Key facts
- Provectus Algae’s last known valuation is $22.8M (Apr 2025).
- It has raised $27.7M; the latest was Grant ($2.5M) in Jul 2025.
- Notable investors include Acequia Capital, Possible Ventures, Hitachi Ventures, At One Ventures, Maropost Ventures — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Provectus Algae
- ·The full record, as it builds
Funding rounds
No funding rounds for Provectus Algae are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Provectus Algae
Operator of a microalgae biotechnology company intended to optimize algae for industrial applications. The company develops biosynthetic services from algae for the production of medicines, vaccines, plant-based foods and flavors, and natural biopesticides, as well as for biological treatments for infectious, inflammatory, and cardiovascular diseases, enabling healthcare professionals to discover and commercialize novel bioproducts from algae.
- Sector
- Materials and Resources
- HQ
- Noosaville, Australia
- Founded
- 2018
- Employees
- 23
- Website
- provectusalgae.com/
- Ownership
- Privately Held (backing)
Provectus Algae doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Provectus Algae shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Provectus Algae in its N-PORT filings yet. We sweep new filings monthly.